ASH 2021 | Patient-reported outcomes vs performance-based metrics: the effects of CAR-T therapy on cognition
Surbhi Sidana, MD, Mayo Clinic, Stanford, CA, outlines the preliminary results of a study evaluating patient-reported outcomes versus performance-based metrics on cognition in patients treated with chimeric antigen receptor (CAR) T-cell therapy. Consistent with previous studies, it was found that the quality of life (QoL) decreased during the first weeks of treatment and then gradually returned to baseline. In addition, whilst patients did not report a decline in cognitive ability in the first weeks after CAR T-cell therapy, objective measures of cognition using the NIH toolbox suggested a trend towards a decrease in cognition. Further analyses must be conducted to verify these results. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA
